Keytruda pembrolizumab: Phase I data

Data from 17 evaluable patients with relapsed/refractory MM who failed >=2 prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), in the open-label, dose-escalati...